Harriet Kluger, MD

Professor of Medicine (Medical Oncology); Associate Cancer Center Director for Education and Training; Deputy Section Chief, Medical Oncology

Research Organizations

Medical Oncology: Subset Medical Oncology Faculty

Discovery to Cure Internship

Skin Diseases Research Center, Yale

SPORE in Skin Cancer

Urologic Oncology Program

WHRY Pilot Project Program Investigators

Yale Cancer Center: Developmental Therapeutics

Office of Cooperative Research

Selected Publications

  • PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB. Clin Cancer Res. 2017 Aug 1;23(15):4270-4279
  • Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. Br J Cancer. 2017 Feb 14;116(4):432-440
  • Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM. Pigment Cell Melanoma Res. 2016 Nov;29(6):627-642
  • Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Qian JM, Yu JB, Kluger HM, Chiang VL. Cancer. 2016 Oct;122(19):3051-8
  • Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Lancet Oncol. 2016 Jul;17(7):976-983.
  • Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a STAT3-Mediated Mechanism. Hollander L, Guo X, Velazquez H, Chang J, Safirstein R, Kluger H, Cha C, Desir GV. Cancer Res. 2016 Jul 1;76(13):3884-94
  • PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. N Engl J Med. 2016 Jun 30;374(26):2542-52
  • Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A, Chiang VL, Kluger HM. Cancer Immunol Res. 2016 Mar;4(3):179-82

Edit this profile

Contact Info

Harriet Kluger, MD
Patient Care Location
Yale Cancer CenterYale New Haven Hospital
20 York Street, Ste North Pavilion 4

New Haven, CT 06510
View on map...
Mailing Address
Medical OncologyPO Box 208032
New Haven, CT 06520-8028